Acadian Asset Management
ALXN

Acadian Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Acadian Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,658
Closed -$4.35M – 2150
2021
Q2 		$4.35M Buy
23,658
+187
+0.8% +$32.1K 0.02% 505
2021
Q1 		$3.59M Sell
23,471
-17,111
-42% -$2.65M 0.01% 563
2020
Q4 		$6.34M Sell
40,582
-12,822
-24% -$1.65M 0.02% 438
2020
Q3 		$6.11M Sell
53,404
-5,559
-9% -$600K 0.03% 404
2020
Q2 		$6.62M Buy
+58,963
New +$6.26M 0.03% 421
2017
Q3 		– Sell
-1,316
Closed -$160K – 1595
2017
Q2 		$160K Buy
+1,316
New +$153K ﹤0.01% 973
2015
Q2 		– Sell
-2,902
Closed -$503K – 1553
2015
Q1 		$503K Sell
2,902
-1,022
-26% -$185K ﹤0.01% 770
2014
Q4 		$726K Buy
+3,924
New +$727K ﹤0.01% 703

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Acadian Asset Management's ALXN Position: Q3 2021 in Review

Acadian Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 23,658 shares — an estimated $4.35M sold.

Acadian Asset Management first reported a position in ALXN in Q4 2014 and held it in 8 quarters. The position peaked at $6.62M in Q2 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Acadian Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Acadian Asset Management sold 23,658 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.35M.
  • Acadian Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 8 quarters.
  • Acadian Asset Management's Alexion Pharmaceuticals position peaked at $6.62M in Q2 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Acadian Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.